Diagnostic testing could be the linchpin for developing
precision prevention, therapeutics, treatments, and prognostics in diabetes,
according to an international consensus report.
Precision diagnostics in type
1 and type 2 diabetes has made a great deal of progress, “but at this stage it
remains more theoretical than practical,” Paul Franks, PhD, an adjunct professor
at the Harvard Chan School of Public Health, Boston, and corresponding author of
this report.
Type 1 diabetes might be reclassified into diabetes subtypes in
the coming years. However, “additional diagnostic methods might be applied to
improve the precision of type 1 and 2 diabetes without reclassification,” said
Franks, who heads the genetic and molecular epidemiology unit at Lund University
Diabetes Center, Malm?, Sweden.
The American Diabetes Association (ADA)
Precision Medicine in Diabetes Initiative released this report in partnership
with the European Association for the Study of Diabetes, the first consensus
paper from major diabetes associations, Frank said.
“The concept of precision
diabetes medicine is only just coming of age. We anticipate that the report will
be the springboard for many other related initiatives,” added
Frank.
Precision diagnostics in this area face a number of barriers and
research gaps.
Currently, no immune-based test can sufficiently diagnose type
1 diabetes. Clinicians shouldn’t rely on test results, clinical features, or
prior prevalence in isolation, the authors cautioned. Two factors might assist
in defining etiological subtypes: the age in which an initial islet autoantibody
appears, and type of antibody. Although genetic risk and genetic risk scores
(T1D-GRS) for type 1 diabetes have been well established, “a high T1D-GRS will
have low positive predictive value in patient populations where the overall
prevalence of T1D is low, such as those aged >50 years when diabetes is
diagnosed,” the authors explained.
A major limitation in a diagnosis of type
2 diabetes is that it excludes all known causes of chronic hyperglycemia, said
Franks. A diagnosis of type 2 diabetes also doesn’t include measurement of the
organ- or tissue-specific defects causing the hyperglycemia. Precision
diagnostics that help assign a mechanism of action to diagnosis could aid in
therapeutic decisions, he added.
“Categories based on cluster analysis at
diagnosis can provide insights into likely progression, risk of complications,
and treatment response” of type 2 diabetes, wrote the authors. A limitation of
this approach is its reliance on a fasting C-peptide at the time of diagnosis.
C-peptide assays aren’t used routinely in clinical practice and their
reliability varies among labs. Biomarkers used to define these clusters may also
evolve over time, influenced by treatment or the course of
disease.
“Moreover, the current approaches for clustering in [type 2
diabetes] require continuously distributed data to be categorized, which
typically results in loss of power. Thus, these methods do not yield good
predictive accuracy, a major expectation in precision medicine,” noted the
authors.
While readily available clinical features such as sex, body mass
index and HbA1c results help predict treatment response and progression of
disease, they also pose the disadvantage of changing over time. Genetic data for
type 2 diabetes might help explain the etiological processes of disease—but lack
the predictive accuracy to replace current delineative methods.
The authors
recommended additional studies to help define type 1 and 2 diabetes subtypes and
the best pathways to treatment.
“Many promising biomarkers and approaches may
improve the precision with which diabetes is diagnosed. Importantly, any new
diagnostic approach will need to be compared with existing approaches and shown
to be more accurate” and more cost-effective, said Franks. There should be a
focus not only on diagnosing diabetes, but also assigning the probabilities of
developing micro and/or macrovascular complications.
“Focusing only on
glycaemia is unlikely to be particularly useful for improved prevention and
treatment,” added Franks.